Phase I evaluation of AT-125 single dose every three weeks

A Phase I trial of AT-125 was completed for the bolus dose every three week schedule. Dose limiting toxicity was primarily central nervous system (CNS) in the form of ataxia, confusion, hallucinations and dysarthria. Although this was most severe at doses of 150 mg/m2, lesser symptoms were reported...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 1984-09, Vol.2 (3), p.311-314
Hauptverfasser:	Taylor, S, Belt, R J, Joseph, U, Haas, C D, Hoogstraten, B
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - adverse effects Central Nervous System - drug effects Drug Administration Schedule Drug Evaluation Glutamine - antagonists & inhibitors Humans Isoxazoles - administration & dosage Isoxazoles - adverse effects Middle Aged Neoplasms - drug therapy Oxazoles - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	314
container_issue	3
container_start_page	311
container_title	Investigational new drugs
container_volume	2
creator	Taylor, S Belt, R J Joseph, U Haas, C D Hoogstraten, B
description	A Phase I trial of AT-125 was completed for the bolus dose every three week schedule. Dose limiting toxicity was primarily central nervous system (CNS) in the form of ataxia, confusion, hallucinations and dysarthria. Although this was most severe at doses of 150 mg/m2, lesser symptoms were reported at all dose levels. Nausea and vomiting were moderate to severe at higher doses. Myelosuppression did not occur. This schedule is not recommended for Phase II studies until methods are developed to reduce drug-related CNS toxicity.
doi_str_mv	10.1007/BF00175382
format	Article
fullrecord	<record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00175382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>6511237</sourcerecordid><originalsourceid>FETCH-LOGICAL-c197t-b140fe2c89fa4e24a0c708ca42e1cbce1f832ce2144aff9f31cbe9a000a51aea3</originalsourceid><addsrcrecordid>eNpFj0FLw0AQhRdRaq1evAt7FqIzu5ts1lstVgsFPdRzmGxnbbRtSjat9N8badHTg8fH431CXCPcIYC9fxwDoE11rk5EH1OrE8hMdir6gJlNMufsubiI8RMAtLOmJ3pZiqi07YuHtwVFlhPJO1puqa3qtayDHM4SVKmM1fpjyXJedwjvuNnLdtEwy2_mr3gpzgItI18dcyDex0-z0UsyfX2ejIbTxKOzbVKigcDK5y6QYWUIvIXck1GMvvSMIdfKs0JjKAQXdNeyo-4rpUhMeiBuD7u-qWNsOBSbplpRsy8Qil__4t-_g28O8GZbrnj-hx6F9Q9iOVPv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase I evaluation of AT-125 single dose every three weeks</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Taylor, S ; Belt, R J ; Joseph, U ; Haas, C D ; Hoogstraten, B</creator><creatorcontrib>Taylor, S ; Belt, R J ; Joseph, U ; Haas, C D ; Hoogstraten, B</creatorcontrib><description>A Phase I trial of AT-125 was completed for the bolus dose every three week schedule. Dose limiting toxicity was primarily central nervous system (CNS) in the form of ataxia, confusion, hallucinations and dysarthria. Although this was most severe at doses of 150 mg/m2, lesser symptoms were reported at all dose levels. Nausea and vomiting were moderate to severe at higher doses. Myelosuppression did not occur. This schedule is not recommended for Phase II studies until methods are developed to reduce drug-related CNS toxicity.</description><identifier>ISSN: 0167-6997</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1007/BF00175382</identifier><identifier>PMID: 6511237</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Antibiotics, Antineoplastic - administration & dosage ; Antibiotics, Antineoplastic - adverse effects ; Central Nervous System - drug effects ; Drug Administration Schedule ; Drug Evaluation ; Glutamine - antagonists & inhibitors ; Humans ; Isoxazoles - administration & dosage ; Isoxazoles - adverse effects ; Middle Aged ; Neoplasms - drug therapy ; Oxazoles - adverse effects</subject><ispartof>Investigational new drugs, 1984-09, Vol.2 (3), p.311-314</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c197t-b140fe2c89fa4e24a0c708ca42e1cbce1f832ce2144aff9f31cbe9a000a51aea3</citedby><cites>FETCH-LOGICAL-c197t-b140fe2c89fa4e24a0c708ca42e1cbce1f832ce2144aff9f31cbe9a000a51aea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6511237$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taylor, S</creatorcontrib><creatorcontrib>Belt, R J</creatorcontrib><creatorcontrib>Joseph, U</creatorcontrib><creatorcontrib>Haas, C D</creatorcontrib><creatorcontrib>Hoogstraten, B</creatorcontrib><title>Phase I evaluation of AT-125 single dose every three weeks</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><description>A Phase I trial of AT-125 was completed for the bolus dose every three week schedule. Dose limiting toxicity was primarily central nervous system (CNS) in the form of ataxia, confusion, hallucinations and dysarthria. Although this was most severe at doses of 150 mg/m2, lesser symptoms were reported at all dose levels. Nausea and vomiting were moderate to severe at higher doses. Myelosuppression did not occur. This schedule is not recommended for Phase II studies until methods are developed to reduce drug-related CNS toxicity.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibiotics, Antineoplastic - administration & dosage</subject><subject>Antibiotics, Antineoplastic - adverse effects</subject><subject>Central Nervous System - drug effects</subject><subject>Drug Administration Schedule</subject><subject>Drug Evaluation</subject><subject>Glutamine - antagonists & inhibitors</subject><subject>Humans</subject><subject>Isoxazoles - administration & dosage</subject><subject>Isoxazoles - adverse effects</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Oxazoles - adverse effects</subject><issn>0167-6997</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFj0FLw0AQhRdRaq1evAt7FqIzu5ts1lstVgsFPdRzmGxnbbRtSjat9N8badHTg8fH431CXCPcIYC9fxwDoE11rk5EH1OrE8hMdir6gJlNMufsubiI8RMAtLOmJ3pZiqi07YuHtwVFlhPJO1puqa3qtayDHM4SVKmM1fpjyXJedwjvuNnLdtEwy2_mr3gpzgItI18dcyDex0-z0UsyfX2ejIbTxKOzbVKigcDK5y6QYWUIvIXck1GMvvSMIdfKs0JjKAQXdNeyo-4rpUhMeiBuD7u-qWNsOBSbplpRsy8Qil__4t-_g28O8GZbrnj-hx6F9Q9iOVPv</recordid><startdate>198409</startdate><enddate>198409</enddate><creator>Taylor, S</creator><creator>Belt, R J</creator><creator>Joseph, U</creator><creator>Haas, C D</creator><creator>Hoogstraten, B</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>198409</creationdate><title>Phase I evaluation of AT-125 single dose every three weeks</title><author>Taylor, S ; Belt, R J ; Joseph, U ; Haas, C D ; Hoogstraten, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c197t-b140fe2c89fa4e24a0c708ca42e1cbce1f832ce2144aff9f31cbe9a000a51aea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibiotics, Antineoplastic - administration & dosage</topic><topic>Antibiotics, Antineoplastic - adverse effects</topic><topic>Central Nervous System - drug effects</topic><topic>Drug Administration Schedule</topic><topic>Drug Evaluation</topic><topic>Glutamine - antagonists & inhibitors</topic><topic>Humans</topic><topic>Isoxazoles - administration & dosage</topic><topic>Isoxazoles - adverse effects</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Oxazoles - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taylor, S</creatorcontrib><creatorcontrib>Belt, R J</creatorcontrib><creatorcontrib>Joseph, U</creatorcontrib><creatorcontrib>Haas, C D</creatorcontrib><creatorcontrib>Hoogstraten, B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taylor, S</au><au>Belt, R J</au><au>Joseph, U</au><au>Haas, C D</au><au>Hoogstraten, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase I evaluation of AT-125 single dose every three weeks</atitle><jtitle>Investigational new drugs</jtitle><addtitle>Invest New Drugs</addtitle><date>1984-09</date><risdate>1984</risdate><volume>2</volume><issue>3</issue><spage>311</spage><epage>314</epage><pages>311-314</pages><issn>0167-6997</issn><eissn>1573-0646</eissn><abstract>A Phase I trial of AT-125 was completed for the bolus dose every three week schedule. Dose limiting toxicity was primarily central nervous system (CNS) in the form of ataxia, confusion, hallucinations and dysarthria. Although this was most severe at doses of 150 mg/m2, lesser symptoms were reported at all dose levels. Nausea and vomiting were moderate to severe at higher doses. Myelosuppression did not occur. This schedule is not recommended for Phase II studies until methods are developed to reduce drug-related CNS toxicity.</abstract><cop>United States</cop><pmid>6511237</pmid><doi>10.1007/BF00175382</doi><tpages>4</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0167-6997
ispartof	Investigational new drugs, 1984-09, Vol.2 (3), p.311-314
issn	0167-6997 1573-0646
language	eng
recordid	cdi_crossref_primary_10_1007_BF00175382
source	MEDLINE; SpringerLink Journals
subjects	Adult Aged Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - adverse effects Central Nervous System - drug effects Drug Administration Schedule Drug Evaluation Glutamine - antagonists & inhibitors Humans Isoxazoles - administration & dosage Isoxazoles - adverse effects Middle Aged Neoplasms - drug therapy Oxazoles - adverse effects
title	Phase I evaluation of AT-125 single dose every three weeks
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T01%3A51%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20I%20evaluation%20of%20AT-125%20single%20dose%20every%20three%20weeks&rft.jtitle=Investigational%20new%20drugs&rft.au=Taylor,%20S&rft.date=1984-09&rft.volume=2&rft.issue=3&rft.spage=311&rft.epage=314&rft.pages=311-314&rft.issn=0167-6997&rft.eissn=1573-0646&rft_id=info:doi/10.1007/BF00175382&rft_dat=%3Cpubmed_cross%3E6511237%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6511237&rfr_iscdi=true